What is CUSIP 00973N102?

CUSIP 00973N102 is the security identifier used in SEC filing datasets for AKTSQ - Aktis Oncology, Inc. - Common Stock, par value $0.0001 per share.

Security Snapshot

Aktis Oncology, Inc. - Common Stock, par value $0.0001 per share (AKTSQ) Institutional Ownership

Q: Who owns AKTSQ - Aktis Oncology, Inc. - Common Stock, par value $0.0001 per share based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 00973N102

13F Institutional Holders and Ownership History from Q1 2017 to Q2 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.01

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, par value $0.0001 per share
Symbol: AKTSQ
Shares outstanding: 53,401,149
SEC-reported price per share: $0.01

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

AKTSQ - Aktis Oncology, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 00973N102.
Latest finished 13F holder period is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 2 to 0 between Q1 2025 and Q2 2025.
SEC-reported value moved from $186 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

00973N102

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

AKTSQ full holder history Aktis Oncology, Inc. SEC filings Aktis Oncology, Inc. company facts Aktis Oncology, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 00973N102:

Q2 2025 (0 holders) Q1 2025 (2 holders) Q4 2024 (6 holders) Q3 2024 (74 holders) Q2 2024 (86 holders) Q1 2024 (114 holders) Q4 2023 (109 holders) Q3 2023 (115 holders) Q2 2023 (129 holders) Q1 2023 (134 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

AKTSQ

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
MPM BIOVENTURES 2018, L.P.	19%	$102,601	10,260,064	ANSBERT GADICKE	12 Jan 2026
ELI LILLY & Co	12%	$63,441	6,344,114	Eli Lilly and Company	12 Jan 2026
Blue Owl Capital Holdings LP	5.9%	$31,613	3,161,348	Blue Owl Capital Holdings LP	31 Mar 2026

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

n/a

Rows shown

1-25 of 34

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q2	0	$0	-$186			$0.01	0
2025 Q1	28,756	$186	-$2,201			$0.01	2
2024 Q4	506,064	$2,329	-$1,774,940	$0	$0	$0.00	6
2024 Q3	21,200,599	$1,897,435	-$265,185	$4,368	$2,300	$0.09	74
2024 Q2	22,552,604	$2,969,307	-$6,536,132	$105	$8,561	$0.13	86
2024 Q1	40,766,012	$24,082,620	+$6,776,273	$1,360	$17,437	$0.59	114
2023 Q4	28,647,438	$23,897,708	-$3,342,214	$17,014	$120,748	$0.83	109
2023 Q3	32,959,953	$24,819,558	-$16,320,918	$48,163	$51,459	$0.75	115
2023 Q2	37,359,126	$118,771,428	+$4,954,833	$234,860	$2,310,502	$3.18	129
2023 Q1	35,816,573	$110,320,654	+$32,393,447	$2,275,100	$2,483,760	$3.08	134
2022 Q4	25,954,942	$73,192,741	-$3,031,899	$64,014	$9,306	$2.82	118
2022 Q3	28,084,792	$83,413,629	-$1,955,518	$125,000	$94,000	$2.97	116
2022 Q2	28,645,141	$105,984,283	-$2,055,220	$208,000	$64,000	$3.70	117
2022 Q1	28,817,875	$187,242,534	+$9,205,739	$630,000	$418,000	$6.50	125
2021 Q4	27,471,896	$181,648,914	+$4,764,811	$704,000	$591,000	$6.68	144
2021 Q3	26,199,923	$251,078,561	+$15,102,389	$1,053,000	$3,599,000	$9.70	137
2021 Q2	24,628,830	$262,680,830	+$18,492,366	$2,515,000	$2,943,000	$10.71	135
2021 Q1	20,871,341	$278,313,970	+$45,493,984	$2,806,000	$1,884,000	$13.34	140
2020 Q4	17,587,930	$215,095,371	+$34,918,930	$1,154,000	$2,098,000	$12.23	123
2020 Q3	14,858,398	$121,245,735	-$9,234	$739,000	$349,000	$8.16	106
2020 Q2	14,645,331	$121,388,588	+$6,390,914	$555,000	$457,000	$8.29	107
2020 Q1	14,541,971	$77,997,627	-$7,393,657	$127,000	$82,000	$5.37	92
2019 Q4	14,861,013	$118,892,872	+$41,772,041	$142,000	$91,000	$8.00	98
2019 Q3	9,599,971	$74,368,610	-$10,612,495	$275,000	$104,000	$7.75	86
2019 Q2	11,160,282	$71,421,311	+$28,509,937			$6.40	74